Dark

Check out our Level2View

ORPH
Orphazyme A/S
stock NASDAQ

Inactive

Mar 30, 2022

0.8700USD-2.247%(-0.0200)941,412

Pre-market

0.00USD-100.000%(-0.89)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 19, 2022

07:40AM EST The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data Benzinga

Jan 18, 2022

04:19PM EST Orphazyme Narrows FY21 Guidance: Net Sales From DKK 30M-DKK40M To DKK35M-DKK37M, Improves Operating Loss Guidance From DKK670M-DKK700M To DKK630-DKK640M Benzinga

Dec 9, 2021

09:46PM EST The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO Benzinga

Nov 4, 2021

08:25AM EDT Orphazyme Filing Shows Registration For $50M Ordinary Share Offering Benzinga

Nov 1, 2021

06:12AM EDT The following are some of the stocks making big moves in Monday's pre-market trading (as of 05.50 A.M. EDT). RTTNews

05:22AM EDT Shares of Orphazyme Rise 25% Premarket; Co on Sunday Announced Progress Made in Understanding Potential Resolution of Topics Outlined in Complete Response Letter from FDA, Including Need for Additional Data to Support NDA Benzinga

Oct 15, 2021

04:21PM EDT Orphazyme Files For $75M Offering Benzinga

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Aug 31, 2021

10:17PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

01:06AM EDT Orphazyme H1 Net Loss DKK 463.8 Mln Or DKK 13.27/Shr Vs Loss Of DKK 251.4 Mln Or DKK 9.77/Shr Last Year RTTNews

Aug 24, 2021

09:37AM EDT CytRx Highlights Orphazyme's Published Results From Its Phase 2/3 Trial Of Arimoclomol In Niemann-Pick Disease Type C Benzinga

08:05AM EDT CytRx Highlights Orphazyme's Published Results From Phase 2/3 Trial Of Arimoclomol In Niemann-Pick Disease Type C RTTNews

08:00AM EDT CytRx Highlights Orphazyme's Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C Business Wire

04:29AM EDT Earnings Scheduled For August 24, 2021 Benzinga

Aug 23, 2021

05:07AM EDT Orphazyme Announces Publication of Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-pick Disease Type C in the Journal of Inherited Metabolic Disease; Trial Demonstrated a Statistically Significant and Clinically Meaningful Treatment Effect of Arimoclomol in NPC Benzinga

Aug 13, 2021

08:59PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Aug 10, 2021

02:42PM EDT The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs Benzinga

02:42PM EDT Orphazyme To Cut Two-Third Workforce Under Restructuring; Reaffirms FY21 Outlook Benzinga

Aug 6, 2021

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 4, 2021

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

Aug 3, 2021

10:00AM EDT ORPH, YMM & BZ Class Action Reminders and Upcoming Deadlines: GlobeNewswire Inc

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 26, 2021

02:12PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Jul 21, 2021

11:06AM EDT Orphazyme Option Alert: Aug 20 $7.5 Calls Sweep (38) near the Ask: 900 @ $0.551 vs 2049 OI; Earnings 8/24 Before Open Ref=$5.84 Benzinga

Jul 15, 2021

06:42PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Jul 12, 2021

10:00PM EDT ORPHAZYME ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Orphazyme A/S and Encourages Investors to Contact the Firm Business Wire

Jul 9, 2021

10:04PM EDT Pomerantz Law Firm Announces the Filing of a Class Action Against Orphazyme A/S PR Newswire

07:27AM EDT AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the companys drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza. GlobeNewswire Inc

Jun 29, 2021

11:05AM EDT Shares of Orphazyme A/S (ORPH) are gaining over 12% on Tuesday morning. The late-stage biopharmaceutical company on Monday revealed plans to lay off most of its employees due to a series of failures for its lead investigational product. The company also presented 36-month data supporting durable response to arimoclomol, its lead candidate. RTTNews

08:37AM EDT Orphazyme Granted U.S. Patent Titled 'Use of Hsp70 as a regulator of enzymatic activity' Benzinga

Jun 28, 2021

06:52AM EDT Orphazyme To Cut Two-Third Workforce Under Restructuring; Reaffirms FY21 Outlook Benzinga

01:11AM EDT Orphazyme A/S' (ORPH), a late-stage biopharmaceutical company, announced Monday that it plans approximate two thirds reduction in its global workforce due to a restructuring aiming to advance its corporate strategy and the development of arimoclomol for Niemann-Pick disease type C or NPC. RTTNews

12:38AM EDT Orphazyme Announces Restructuring To Focus Resources On Supporting Path Forward For Arimoclomol RTTNews

Jun 25, 2021

03:59PM EDT Orphazyme Option Alert: Jul 16 $7.5 Puts Sweep (5) near the Bid: 211 @ $1.298 vs 3714 OI; Ref=$7.66 Benzinga

Jun 24, 2021

10:16AM EDT Orphazyme US Patent & Trademark Office Abstract For Co.'s 'HEAT SHOCK PROTEINS AND CHOLESTEROL HOMEOSTASIS' Benzinga

04:56AM EDT The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 4.55 A.M.) RTTNews

Jun 23, 2021

10:17AM EDT Orphazyme Option Alert: Jul 16 $7.5 Puts Sweep (3) near the Bid: 483 @ $1.9 vs 3085 OI; Ref=$6.57 Benzinga

06:08AM EDT Orphazyme Announced Goldman Sachs Aggregate Holding of Shares and Financial Instruments in the Company Increased to 5.8% as of June 16, 2021 and was Reduced to Less than 5% as of June 17, 2021 Benzinga

Jun 18, 2021

04:30PM EDT CytRx Comments On Orphazyme Complete Response Letter From FDA Benzinga

03:05PM EDT Mid-Afternoon Market Update: Dow Tumbles Over 400 Points; CAI International Shares Spike Higher Benzinga

12:18PM EDT Mid-Day Market Update: Crude Oil Rises Over 1%; Orphazyme Shares Plunge Benzinga

10:40AM EDT Mid-Morning Market Update: Markets Open Lower; Adobe Reports Upbeat Q2 Earnings Benzinga

09:44AM EDT Orphazyme Option Alert: Jul 16 $17.5 Calls Sweep (3) near the Ask: 200 @ $1.25 vs 636 OI; Ref=$8.2728 Benzinga

07:59AM EDT Benzinga Pro's Top 5 Stocks To Watch For Friday, Jun. 18, 2021: ORPH, VXRT, STLD, HOFV, TAL Benzinga

07:46AM EDT The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs Benzinga

07:19AM EDT U.S. Equity Futures Flat; Orphazyme Shares Lose More than Half Their Value Following FDA Complete Response Letter; Gold Futures Rise 1% Benzinga

07:19AM EDT U.S. Equity Flat; Orphazyme Shares Lose More than Half Their Value Following FDA Complete Response Letter; Gold Futures Rise 1% Benzinga

06:28AM EDT Orphazyme Wild Party At Risk As FDA Rejects Its Rare Neurodegenerative Disease Drug Benzinga

05:18AM EDT Orphazyme Cut its Outlook for FY 2021 Following FDA CRL Benzinga

05:15AM EDT Orphazyme Shares Fall 55% Premarket After Co Announced it Received a Complete Response Letter From the FDA for its Treatment for Niemann-Pick Disease Ttype C Benzinga

02:42AM EDT Danish rare disease company Orphazyme AS (ORPH) announced Friday that it has received a Complete Response Letter or CRL from the U.S. Food and Drug Administration following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C or NPC. RTTNews

02:03AM EDT Orphazyme Receives CRL From FDA Following Review Of NDA For Arimoclomol RTTNews

Jun 17, 2021

09:48AM EDT Orphazyme shares were trading lower amid continued volatility and possible profit-taking in the stock after it rallied as investors await the June 17 PDUFA date for Arimocolmol. NOTE: Arimocolmol was developed by CytRx and has been licensed to Orphazyme. Benzinga

Jun 16, 2021

05:56PM EDT Top 3 Penny Stocks to Buy Right Now for Your 2021 Summer Watchlist Benzinga

02:29PM EDT Orphazyme shares are trading higher on abnormally-high volume. Not seeing any company-specific news to justify the price action in the stock. Benzinga

04:29AM EDT Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally Benzinga

Jun 11, 2021

12:02PM EDT Mid-Day Market Update: Markets Mixed; Novan Shares Spike Higher Benzinga

10:50AM EDT Stock Alert: Orphazyme Down 42% RTTNews

08:05AM EDT The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts Benzinga

07:55AM EDT Benzinga Pro's Top 5 Stocks To Watch For Friday, Jun. 11, 2021: BIIB, TTWO, KR, MEDS, ARMK Benzinga

06:39AM EDT Orphazyme Announced Earlier it is Not Aware of Any Material Change in Its Clinical Development Programs, Financial Condition or Results of Operations That Would Explain Recent Price Volatility, Trading Volume Benzinga

Jun 10, 2021

02:30PM EDT Mid-Afternoon Market Update: Nasdaq Rises 100 Points; Materialise Shares Slide Benzinga

12:08PM EDT Mid-Day Market Update: Yiren Digital Rises Following Q1 Results; Ocugen Shares Slide Benzinga

Jun 3, 2021

08:23AM EDT The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout Benzinga

Jun 2, 2021

10:38AM EDT Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates Benzinga

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 13, 2021

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

May 7, 2021

03:03PM EDT Mid-Afternoon Market Update: Dow Surges Over 200 Points; ChemoCentryx Shares Drop Benzinga

12:20PM EDT Mid-Day Market Update: Pro-Dex Rises After Q3 Results; Orphazyme Shares Slide Benzinga

10:21AM EDT Mid-Morning Market Update: Markets Open Higher; US Adds Only 266,000 Jobs In April Benzinga

10:02AM EDT Orphazyme Shares Plummet As Arimoclomol Flunks In Amyotrophic Lateral Sclerosis Study Benzinga

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

Apr 5, 2021

03:12PM EDT Wrapping Up March With With A Steady Green Streak Benzinga

Apr 1, 2021

04:30PM EDT CytRx Notes Orphazyme's Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis Business Wire

Mar 30, 2021

10:19AM EDT Mid-Morning Market Update: Markets Open Lower; McCormick Profit Tops Views Benzinga

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2021 Benzinga

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

07:30AM EDT B of A Securities Downgrades Orphazyme to Underperform, Lowers Price Target to $5 Benzinga

Mar 29, 2021

02:45PM EDT Why Is Orphazyme (ORPH) Stock Trading Lower On Monday? Benzinga

02:34PM EDT Mid-Afternoon Market Update: Dow Rises 50 Points; Orphazyme Shares Plunge Benzinga

12:11PM EDT Mid-Day Market Update: Gold Drops Over 1%; Humanigen Shares Spike Higher Benzinga

10:11AM EDT Mid-Morning Market Update: Markets Mostly Lower; Cal-Maine Foods Reports Mixed Q3 Results Benzinga

02:34AM EDT Orphazyme Says Phase 2/3 Trial Evaluating Arimoclomol Did Not Meet Primary, Secondary Endpoints RTTNews

Mar 25, 2021

01:57PM EDT Orphazyme Announces Resolutions Passed At Annual General Meeting Benzinga

01:56PM EDT Resolutions Passed At Annual General Meeting Benzinga

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

Mar 4, 2021

08:06AM EST Orphazyme Announces The Appointment of Christophe Bourdon As CEO Benzinga

Mar 2, 2021

01:05AM EST Orphazyme FY Net Loss DKK 633.2 Mln Vs Loss Of DKK 337.5 Mln Last Year RTTNews

Mar 1, 2021

01:09AM EST Orphazyme Appoints Christophe Bourdon As CEO, Effective As Of April 1, 2021 RTTNews

Jan 26, 2021

06:17AM EST Orphazyme Issued U.S. Patent #10,898,476 'Heat shock proteins and cholesterol homeostasis' Benzinga

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Dec 31, 2020

02:00PM EST CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C Business Wire

Dec 28, 2020

06:27AM EST A Peek Into The Markets: US Stock Futures Gain As Trump Signs $900B Covid-19 Relief Bill Benzinga

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 22, 2020

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 7, 2020

10:50AM EST CytRx Announces Orphazyme's U.S. Expansion Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C Business Wire

Nov 3, 2020

07:38AM EST The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga

Oct 30, 2020

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

Oct 23, 2020

08:28AM EDT Orphazyme Accelerates Arimoclomol Pre-launch Activities And Updates Financial Outlook For 2020; Updates FY20 Operating Loss Guidance From $80M-$88M To $96M-$104M Benzinga

Oct 5, 2020

11:32AM EDT Orphazyme Issues Press Release Highlighting Danske Banks Holds ~1.15M Shares In Co., Or About 3.31% Of Share Capital Benzinga

Sep 30, 2020

08:25AM EDT CytRx Issues Statement Regarding Orphazyme's Global Offering Benzinga

Sep 29, 2020

10:16AM EDT Orphazyme Shares Open For Trade At $10.80; IPO Priced At $11/Share Benzinga

10:15AM EDT Orphazyme Shares Expected To Open For Trade Today; IPO Priced At $11/ADS Benzinga

Sep 25, 2020

11:00AM EDT CORRECTION: Orphazyme Shares Will Not Open Today, Have Not Priced Yet Benzinga

10:19AM EDT Orphazyme Shares Expected To Open For Trade Today; IPO Priced At $13.13/Share Benzinga

06:39AM EDT Orphazyme Says Will Price Its IPO On Sept. 28, 2020, Subject To Market Conditions; Will Settle Global Offering Oct. 1, 2020 Benzinga

06:29AM EDT UPDATE: Orphazyme Says FDA Set PDUFA Target Date For Arimoclomol Of Mar. 17, 2021 Benzinga

06:29AM EDT Orphazyme Recent Filing, Earlier Press Release Shows Co. Received Communication From FDA Of Acceptance Of Priority Review For Its New Drug Application For Arimoclomol In NPC Benzinga

Share